TSHA stock forecast, quote, news & analysis
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS... Show more
Why Taysha Gene Therapies (TSHA) Stock Is Down -17.6% in the Last 30 Days
Key Takeaways
- TSHA shares fell roughly 17.6% over the trailing 30 days, from a closing price of $5.64 on September 2, 2026 to about $4.65, with the steepest losses concentrated in late September.
- The decline largely reflects a broad risk-off tone across biotechnology and growth equities, rather than a single company-specific setback.
- Competitive overhang from Neurogene (NGNE) and its NGN-401 program has kept sentiment cautious even as TSHA-102 clinical data remained supportive.
- Over the trailing quarter, TSHA has declined roughly 29%, extending a pullback from its late-June peak near $6.94.
- Sell-side consensus remains constructive, but the next major company catalysts are not expected until 2027 interim data and FDA feedback.
Taysha Gene Therapies (TSHA) Company Overview and Market Position
Taysha Gene Therapies, Inc. is a Dallas-based, clinical-stage biotechnology company focused on adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS). Its lead program, TSHA-102, is an intrathecally delivered, self-complementary AAV9 gene therapy in development for Rett syndrome, a rare X-linked neurodevelopmental disorder caused by MECP2 mutations for which no approved disease-modifying therapies exist.
TSHA-102 has received Breakthrough Therapy, Regenerative Medicine Advanced Therapy, Fast Track, Orphan Drug, and Rare Pediatric Disease designations from the FDA. The company's broader pipeline includes TSHA-120 for giant axonal neuropathy (GAN) and TSHA-105 for SLC13A5 deficiency. Investors follow TSHA primarily for the regulatory and commercial prospects of TSHA-102, which targets an estimated 15,000 to 20,000 patients across the U.S., EU, and U.K.
Taysha Gene Therapies (TSHA) Stock Price Performance: Last 30 Days vs. Quarter
Over the trailing 30 days, TSHA moved from a September 2, 2026 close of $5.64 to approximately $4.65, a decline of about 17.6%. The slide was not uniform: shares drifted modestly lower through mid-September before accelerating sharply between September 23 and September 25, when the stock fell from $5.16 to $4.67 in a matter of sessions on elevated volume.
The quarterly picture is weaker still. From an early-July level of roughly $6.53, TSHA has declined approximately 29%. The stock peaked near $6.94 in late June, shortly after the company reported positive longer-term REVEAL Phase 1/2 data and completed dosing in the pivotal trial, and has trended lower through the third quarter despite a series of analyst price-target increases.
What Drove TSHA Stock Price in the Last 30 Days
The most pronounced selling in the 30-day window came during the second half of September and coincided with a broader rotation out of speculative biotechnology and growth names. Rising energy prices, a 10-year Treasury yield that briefly topped 5%, and uncertainty around Federal Reserve policy pressured rate-sensitive, pre-revenue biotech companies, and TSHA traded lower alongside its gene-therapy peer group.
Company-specific news during the period was largely neutral to positive. Wolfe Research initiated coverage of TSHA with an Outperform rating in mid-September, and the stock retains a broadly favorable consensus with an average price target well above its recent trading range. However, investors have continued to weigh competitive risk: Guggenheim research on Neurogene characterized its NGN-401 candidate as potentially best-in-class versus TSHA-102, reinforcing an overhang that has limited upside even as Taysha's own data remained supportive.
What Drove TSHA Stock Performance Over the Last Quarter
The trailing-quarter decline is best understood as a multi-month de-rating after a sharp rally. In late June, TSHA reported that all 12 patients in REVEAL Part A gained or regained at least one developmental milestone, with 310 total functional gains and no treatment-related serious adverse events, and announced completion of dosing in the 17-patient REVEAL pivotal trial. The stock spiked toward $7 before a $230 million public offering of common stock and pre-funded warrants in late June pressured the share price.
Through the third quarter, shares gradually drifted lower as investors processed competitive dynamics in Rett syndrome, particularly around NGN-401, and as macro conditions turned less favorable for long-duration biotech assets. The August expansion of a strategic manufacturing partnership with Catalent and second-quarter financial results did not reverse the trend, leaving TSHA roughly 29% below its early-July level.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-powered trading bots that have demonstrated notable recent performance. While Tickeron offers hundreds of AI robots trading thousands of tickers, only top-performing and most relevant strategies appear in this section, giving traders a focused view of momentum across the market. These bots vary in strategy, holding timeframe, and performance metrics, so investors can compare approaches that range from short-term technical patterns to longer-horizon signals. Reviewing the page can help traders identify which automated strategies are currently gaining traction and evaluate them alongside their own research.
TSHA Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, the most important catalysts for TSHA are clinical and regulatory. The company expects topline data from the REVEAL pivotal trial six-month interim analysis and FDA feedback on the Biologics License Application (BLA) pathway for TSHA-102 in the first half of 2027. A BLA-enabling Process Performance Qualification manufacturing campaign is anticipated in the fourth quarter of 2026, and quarterly earnings updates will continue to provide visibility into cash runway, which management has indicated extends into the second half of 2028.
Investors should also monitor competitive Rett syndrome data, broader interest-rate and risk-appetite dynamics that influence pre-revenue biotech valuations, and any changes in analyst ratings or price targets. These factors, rather than near-term revenue, are likely to drive sentiment until pivotal data arrive.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
TSHA's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for TSHA turned positive on September 29, 2026. Looking at past instances where TSHA's MACD turned positive, the stock continued to rise in 39 of 44 cases over the following month. The odds of a continued upward trend are 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where TSHA's RSI Oscillator exited the oversold zone, 32 of 39 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 54 of 67 cases where TSHA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.
Following a +2.79% 3-day Advance, the price is estimated to grow further. Considering data from situations where TSHA advanced for three days, in 215 of 267 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
TSHA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
TSHA moved below its 50-day moving average on August 26, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TSHA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for TSHA entered a downward trend on October 01, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating steady price growth. TSHA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 61 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.198) is normal, around the industry mean (26.780). P/E Ratio (2.698) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (333.333) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TSHA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology